Multidrug Resistant Tuberculosis Treatment Outcome in Children in Developing and Developed Countries: A Systematic Review and Meta-Analysis Publisher Pubmed



Tola HH^{1, 2} ; Khadoura KJ^{1, 3} ; Jimma W⁴ ; Nedjat S^{1, 5} ; Majdzadeh R^{1, 5}
Source: International Journal of Infectious Diseases Published:2020

Abstract

Background: We aimed to compare and contrast the proportions of treatment outcome between developing and developed countries in children treated for multidrug resistance tuberculosis (MDR-TB). Methods: We conducted a systematic review and meta-analysis of articles published on children treated for MDR-TB. We searched published articles from electronic databases: PubMed/Medline, EMBASE, Scopus and Web of Science for English articles without restricting publication year. We employed random-effects meta-analysis model to estimate the pooled proportions of treatment success, death, treatment failure and lost to follow up. Results: We pooled data of 1,343 children obtained from 17 included studies, and the overall pooled treatment success was 77.0% (95% Confidence Interval (CI), 69.0–85.0). Pooled treatment success in developing countries was 73.0% (63.0–83.0), while in developed countries 87.0% (81.0–94.0). The overall pooled treatment failure was 3.0% (1.0–6.0), while death 8.0% (4.0–11.0) and lost to follow up 10.0% (6.0–4). Conclusion: MDR-TB treatment success in children is well achieved in both developed and developing countries by currently available drugs. Improving MDR-TB treatment programme is vital to achieve the maximum treatment successful. Promoting research on pediatric MDR-TB treatment outcome could also help to fill evidence gap. © 2020 The Author(s)